NCT04552795View on ClinicalTrials.gov

Pilot Study to Investigate the Safety and Feasibility of AntiRetroviral Therapy for Alzheimer's Disease

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

February 15, 2021

Primary Completion Date

May 4, 2023

Study Completion Date

November 4, 2023

Conditions
Alzheimer Disease, Early Onset
Interventions
DRUG

3TC

12 subjects will be administered 3TC, 300mg once daily, via an oral tablet for 24 weeks.

Trial Locations (3)

78229

Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases, San Antonio

Sam and Ann Barshop Institute for Longevity & Aging Studies, San Antonio

University of Texas Health Science Center at San Antonio, San Antonio

All Listed Sponsors
collaborator

Owens Medical Research Foundation

OTHER

lead

The University of Texas Health Science Center at San Antonio

OTHER

NCT04552795 - Pilot Study to Investigate the Safety and Feasibility of AntiRetroviral Therapy for Alzheimer's Disease | Biotech Hunter | Biotech Hunter